Scarica l'app Stockscreener
0.4081
9.03%
-0.0405
Bioatla Inc Borsa (BCAB) Ultime notizie
What Are You Thinking About Investing In BioAtla Inc (NASDAQ: BCAB) Stock? - Stocks Register
Market Momentum Report: BioAtla Inc (BCAB)’s Negative Close at 0.45 - The Dwinnex
BioAtla Inc: Navigating a Turbulent Year, Up -88.84% from 52-Week Low - The InvestChronicle
BioAtla faces Nasdaq delisting over share price rule - MSN
BioAtla Inc (BCAB) Shares Down Despite Recent Market Volatility - The News Heater
Millennium Management LLC Reduces Stake in BioAtla Inc. - GuruFocus.com
Jane Street Group LLC Decreases Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Stock Price Down 6.1% – Here’s Why - Defense World
Bioatla stock hits 52-week low at $0.57 amid sharp decline - Investing.com
BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
**BioAtla Updates Corporate Presentation in 8-K Filing** - Defense World
BioAtla Announces Registered Direct Offering to Advance Clinical Programs to Key Inflection PointsSan Diego, Calif., December 20, 2024 – BioAtla, Inc. (NASDAQ: BCAB), a global clinical-stage biotechnology company, disclosed on December 19, 2024, that - Defense World
Bioatla stock hits 52-week low at $1.02 amid market challenges - Investing.com Australia
BioAtla Secures $9.2M for Clinical Program Advancements - TipRanks
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points - The Manila Times
BioAtla Highlights Advancements in CAB Cancer Therapy - TipRanks
BioAtla announces $9.2 million stock and warrant sale - Investing.com
BioAtla announces $9.2 million stock and warrant sale By Investing.com - Investing.com Canada
BioAtla announces registered direct offering to advance two mid-stage clinical programs, shares fall - Seeking Alpha
BioAtla Secures $9.2M Funding Through Strategic Stock Offering to Advance Clinical Programs - StockTitan
Insiders Give Up US$66k As BioAtla Stock Drops To US$1.31 - Yahoo Finance
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting - The Manila Times
BioAtla's Lung Cancer Drug Shows Promising 58% One-Year Survival Rate in Key Clinical Data - StockTitan
BioAtla's SWOT analysis: oncology biotech stock faces pivotal year By Investing.com - Investing.com South Africa
BioAtla's SWOT analysis: oncology biotech stock faces pivotal year - Investing.com
BCABBioAtla, Inc. Latest Stock News & Market Updates - StockTitan
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting - Quantisnow
BioAtla, Inc. (NASDAQ:BCAB) Q3 2024 Earnings Call Transcript - MSN
Michael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 trades - MSN
GSA Capital Partners LLP Purchases New Position in BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
BioAtla, Inc. (NASDAQ:BCAB) Sees Significant Drop in Short Interest - MarketBeat
HC Wainwright Weighs in on BioAtla FY2024 Earnings - Defense World
FY2024 Earnings Estimate for BioAtla Issued By HC Wainwright - MarketBeat
Analysis of TANG CAPITAL MANAGEMENT LLC's Recent Transaction in BioAtla Inc - GuruFocus.com
BioAtla (NASDAQ:BCAB) Rating Lowered to Neutral at HC Wainwright - Defense World
Michael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 trades (HPP:NYSE) - Seeking Alpha
HC Wainwright & Co. Downgrades BioAtla (BCAB) - MSN
BioAtla (NASDAQ:BCAB) Downgraded to "Neutral" Rating by HC Wainwright - MarketBeat
BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Head to Head Review: Alector (NASDAQ:ALEC) vs. BioAtla (NASDAQ:BCAB) - Defense World
3 Promising US Penny Stocks With At Least $90M Market Cap - Simply Wall St
BioAtla Reports Q3 2024 Financial Results and Clinical Advances - TipRanks
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):